Compare Rivian Automotive, Inc. (RIVN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs GeneDx Holdings Corp — how do they compare? Rivian Automotive, Inc. trades at $13.96 (market cap $20.75B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Rivian Automotive, Inc. is far larger — about 10.3× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rivian Automotive, Inc. for 61 Days and GeneDx Holdings Corp for 19 Days on average.
| RIVN | WGS | |
|---|---|---|
Market Cap | $20.75B | $2.02B |
Volume | 26,144,654 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $167.51 |
52-Week Low | $12.50 | $34.51 |
Typical Hold Time | 61 Days | 19 Days |
Enterprise Value | $20.79B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian (RIVN) trades at $14.33, down 0.07% on the day, with a bearish technical signal from moving averages. The company reported record Q3 2026 deliveries of 19,248 vehicles, beating estimates, but maintained full-year guidance, causing mixed market reactions. Financially, revenue growth continues while losses narrow, with a net income margin of -54.95% in 2025. Analyst consensus is a Buy with a $16.89 price target, though cash burn remains a concern with negative operating cash flow.
Rivian's outlook hinges on scaling R2 production and advancing autonomy, offering growth potential, but high cash burn, competitive pressures, and execution risks pose significant challenges. The stock presents a speculative opportunity for investors betting on EV adoption and operational improvements, balanced by substantial financial and market volatility risks.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
